glp-1

The distinction between lifespan, defined as total years lived, and healthspan, defined as years lived in good health and functional independence, has emerged as a central framework for understanding global ageing.  Advances in sanitation, infectious disease control, and acute medical care have substantially increased life expectancy worldwide.  However, these gains have been accompanied by a… Read more »

In December 2025, the World Health Organisation (WHO) issued its first guidance on using Glucagon-Like Peptide 1 (GLP 1) therapies for treating obesity 1.  The GLP-1 medications covered include liraglutide (Saxenda), semaglutide (Wegovy), and tirzepatide (Mounjaro / Zepbound in the US). Obesity is a complex chronic disease and a major driver of non-communicable diseases, including… Read more »

Introduction The therapeutic approach to obesity and type 2 diabetes mellitus (T2DM) is evolving in a similar way to how clinicians use antibiotics: targeting several pathways that often produce stronger and more durable effects than acting on a single pathway.   Glucagon-like peptide-1 receptor agonists (GLP-1RAs) laid the foundation, but the complexity of fat mass… Read more »

Here is another opportunity to read the most viewed KHNI articles in 2025:  Sustainable Nutrition – What Does It Mean and How Do We Take Action? What is Vitamin K2, and What Role Does It Have in Health?  The FODMAP Diet for IBS – An FAQ  Acacia’s Role as a Functional Fibre GLP-1 Drugs: Bridging… Read more »

Globally, there are approximately 2.1 billion adults who currently are overweight or have obesity.  It is forecast that this will substantially rise to around 3.2 billion by 2050 – accounting for almost 60% of the adult population 1.  This highlights that traditional approaches to curbing the prevalence of overweight and obesity have had limited success. … Read more »

 On October 14th, 2025, the KHNI hosted an expert scientific webinar; “Adapting Appetites: Scientific and Industry Perspectives on the rise of GLP-1 Medications”.  The expert panel explored the latest science behind Glucagon Like Peptide-1s (GLP-1s), consumer behaviours across regions, the unique nutritional needs of users and what this means for future innovation in food… Read more »

    On April 8th, 2025, the Kerry Health and Nutrition Institute (KHNI) hosted a webinar titled “What’s Shaping the Future of Food: Key Health and Nutrition Trends for 2025.”  Experts in neuroscience, nutrition, food science, and sports performance explored how evolving science and consumer needs are shaping the future of food.  Dr. Laura Collins… Read more »